TMO — Q3 2026 Financial Report Analysis

Thermo Fisher's third quarter of 2026 (the three months ended September 26, 2026) brought in $12.14 billion of revenue, up 9% from $11.12 billion a year earlier, and GAAP diluted earnings per share (EPS) of $4.64, up 9%. The underlying business sped up again: organic growth (sales growth with acquisitions, disposals and currency swings stripped out) was 6%, after 1% in the first quarter and 5% in the second. Operating income rose much faster than revenue, 17%, but a higher tax rate and higher interest costs absorbed about half of that before it reached EPS.

This analysis is based on the earnings release (Exhibit 99.1 to the 8-K filed October 21, 2026). The full 10-Q has not been filed yet, so the organic growth of each segment, management's explanation of each segment's results, and the tax-rate commentary are not available yet.

The numbers

Percentages are calculated from the dollar figures in the release; Thermo Fisher, working from unrounded amounts, presents them as 9% revenue growth, 9% GAAP EPS growth and 15% adjusted EPS growth. "pt" means percentage point. Free cash flow is operating cash flow minus spending on property and equipment.

For the first nine months, revenue was $35.14 billion (+8.6%), organic growth 4%, GAAP diluted EPS $13.75 (+9.7%) and adjusted EPS $18.15 (+11.3%).

Where the growth came from

Thermo Fisher reports four segments. "Segment margin" is each segment's operating income before amortisation, restructuring and certain other charges, as a share of its revenue; it is the basis management uses to judge each business.

The release does not split each segment's growth into organic, acquired and currency parts; that detail comes with the 10-Q. What can be read from the table:

• Laboratory Products & Biopharma Services (57% of revenue) grew 15% and added $893 million of the company's $1,015 million revenue increase. Much of that is Clario, the clinical-trial data business bought on March 24, 2026, which will count as acquired growth until it has been owned for a year. Segment income rose 23% to $1,067 million and the margin reached 15.5%, up from 14.5% a year ago and from 14.0% in Q2.
• Analytical Instruments grew 5.8% to $2.00 billion, and its segment income rose 25% to $538 million. In Q2 all of this segment's growth was organic, and currency had no net effect at the company level this quarter, so most of the 5.8% is likely organic, but the 10-Q will confirm it. Instruments are big-ticket equipment that labs delay buying when budgets are tight, so a second quarter of mid-single-digit growth with a much higher margin is a meaningful sign that lab spending is holding up.
• Specialty Diagnostics revenue fell 6.5% to $1.10 billion while its segment income rose 6% to $341 million. The likely reason for the revenue drop is portfolio, not demand: the microbiology business, part of this segment, was sold during the quarter. The release does not quantify how much revenue left with it.
• Life Sciences Solutions grew 5.1%. The filtration business bought from Solventum in September 2025, which drove most of this segment's 13% growth in Q2, is now mostly in the year-ago base, so this quarter's growth is closer to the segment's own pace.

Margins: lower costs relative to sales almost everywhere

In the release's income statement, cost of revenues fell to 57.2% of revenue from 58.2%, selling, general and administrative costs (sales, marketing and overheads) to 15.3% from 16.1%, and research and development to 2.9% from 3.1%. Working the other way, amortisation of acquired intangible assets rose to 4.3% of revenue from 3.9% ($519 million vs $435 million, mainly from adding Clario) and restructuring and other costs to 1.6% from 1.2%. The release's line items are grouped differently from the 10-Q's, so these ratios should not be compared with the cost ratios in our Q2 analysis.

The adjusted operating margin rose 1.2 points to 24.5%, the same improvement as the GAAP margin, so the gain is in the day-to-day business rather than in lower one-off charges. The release itself attributes performance to its "PPI Business System" (the company's in-house productivity programme) but gives no segment-level explanation; the 10-Q's segment commentary will say how much came from volume, productivity, mix and currency.

Takeaway: Thermo Fisher's growth is broadening, not just being bought. Organic growth reached 6%, Analytical Instruments' margin rose 4.3 points, and Laboratory Products & Biopharma Services, where Clario sits, raised its margin a full point. The quarter's weak spot is below the operating line: tax and interest turned 17% operating income growth into 9% EPS growth, and with no share buybacks in the quarter, that gap is unlikely to close quickly.

What the headline numbers hide

Tax is the main reason GAAP EPS lagged. Income before tax rose 14.3% to $2,088 million, but the tax charge rose to $352 million from $207 million, a GAAP tax rate of 16.9% against 11.3%. In Q2 the rate was 8.7%, helped by one-off deferred tax benefits. Had the rate stayed at last year's 11.3%, net income would have been about $115 million (roughly $0.31 per share) higher. Part of this is items the company treats as one-offs: its tax adjustment added $27 million to adjusted net income this year, against a $64 million deduction a year ago, a swing of about $0.24 per share. On the company's adjusted basis the tax rate was about 11.6% against 11.0% (our calculation from the reconciliation), so the underlying tax headwind is small. The release does not explain the GAAP tax charge.

Interest costs are higher after the Clario deal. Interest expense rose to $417 million from $347 million while interest income rose only to $252 million from $234 million, so net interest expense went to $165 million from $113 million. Together with a $9 million loss from equity investments (vs a $2 million gain), this is why income before tax grew 14% while operating income grew 17%.

Buybacks added about 2 points of EPS growth, from earlier purchases. Diluted shares were 371 million against 378 million, which turned 6.5% net income growth into 8.7% EPS growth. But nine-month share repurchases were $4.00 billion, exactly the first-half figure, so the company bought back no shares in Q3.

The GAAP vs adjusted gap widened to $2.04 per share from $1.52. Adjusted EPS leaves out: amortisation of acquired intangibles, a non-cash charge that spreads the cost of acquired customer relationships and technology over time ($1.40 per share, up from $1.15); restructuring and other costs ($0.54, up from $0.36); smaller cost-of-revenue, investment and equity-earnings items; and the tax effects above. The $199 million restructuring line nets two portfolio items: a $244 million loss on a business classified as held for sale (written down to the price it is expected to fetch) and a $72 million gain on a business that was sold. Everything else in the line came to a net $27 million. The release does not name either business; the microbiology sale closed during the quarter, and the 10-Q should identify the held-for-sale business.

Cash conversion was strong. Operating cash flow was $2,551 million against $1,727 million of net income in the quarter, and $5,867 million against $5,124 million (115%) for nine months. Nine-month free cash flow rose 39% to $4,618 million, but part of that comes from a timing difference in cash payments. Our Q2 analysis noted that cash tax payments were much lower in the first half than a year earlier; the release does not say whether that reversed in Q3, but quarterly free cash flow growth of 15% is roughly in line with adjusted earnings growth, so Q3 itself does not look flattered.

Receivables and inventory are not a concern. Since December, receivables rose 8.1% to $9,625 million and inventory 4.0% to $5,643 million, against nine-month revenue growth of 8.6%. Both figures include the businesses Thermo Fisher acquired.

The balance sheet improved in the quarter. Cash rose to $5.46 billion from $4.06 billion at the end of Q2, and total debt fell to $41.37 billion from $42.55 billion. The nine-month cash flow statement shows $1.02 billion of proceeds from selling a business, in line with the roughly $1.075 billion microbiology sale price. Debt minus cash fell to about $35.9 billion from about $38.5 billion three months earlier.

Did last time's read hold up?

Our Q2 analysis flagged three things to watch and noted that full-year guidance assumed about 5% organic growth in the second half.

• Organic growth: Q3 delivered 6%, ahead of the pace guidance needed.
• Analytical Instruments: we asked for a second quarter of mid-to-high single-digit organic growth. Reported growth was 5.8% and the margin rose further, to 26.9% from 23.0% in Q2, so this mostly held, pending the 10-Q's organic figure.
• Clario integration: we said margin progress in Laboratory Products & Biopharma Services would justify the $9.1 billion price. The margin rose to 15.5% from 14.0% in Q2: a first sign of progress.
• Less financial slack: we expected future EPS growth to come mainly from operations rather than buybacks or tax. That is what happened: no buybacks in the quarter, a higher tax rate, and operating income doing all of the work.

Outlook and our read

The release does not include guidance; the company said it would update its 2026 outlook on the October 21 earnings call, and those figures are not in the filing. The last guidance we have, from the July call as reported by GenomeWeb, was revenue of $47.4–48.1 billion, adjusted EPS of $24.93–25.33 and organic growth of about 4%.

The arithmetic: nine-month adjusted EPS is $18.15, so the July midpoint ($25.13) needs about $6.98 in Q4, against $6.68 in Q3. Nine-month organic growth is 4%, so the full-year figure is on track for at least that if Q4 grows at Q3's pace. With 6% organic growth and margins rising in every segment, Q3 puts the company at or above the top of its July ranges; whether the call raised them, and by how much, is the first thing to check.

Three things to watch in the Q4 report and the coming 10-Q:

1. Segment organic growth. The 10-Q will show whether Analytical Instruments' 5.8% was all organic, and how much of Laboratory Products & Biopharma Services' 15% came from Clario.
2. The held-for-sale business. A $244 million write-down suggests another disposal is coming. Which business it is, and how much revenue it carries, will affect 2027 growth comparisons.
3. Tax and interest. With the GAAP tax rate at 16.9% this quarter and no buybacks, EPS growth now depends on operating income growth. A return to buybacks, or a lower tax rate, would widen the EPS gain; neither is signalled in the release.